The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes

BACKGROUND: The targeted ERBB2 therapy, trastuzumab, has had a tremendous impact on management of patients with HER2+ breast cancer, leading to development and increased use of further HER2 targeted therapies. The major clinical side effect is cardiotoxicity but the mechanism is largely unknown. On...

Descripción completa

Detalles Bibliográficos
Autores principales: Necela, Brian M., Axenfeld, Bianca C., Serie, Daniel J., Kachergus, Jennifer M., Perez, Edith A., Thompson, E. Aubrey, Norton, Nadine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243239/
https://www.ncbi.nlm.nih.gov/pubmed/28101782
http://dx.doi.org/10.1186/s40169-016-0133-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5243239/
https://www.ncbi.nlm.nih.gov/pubmed/28101782
http://dx.doi.org/10.1186/s40169-016-0133-2

Ejemplares similares